Research & Drug Development

A naturally occurring human steroid for the treatment of neurodegenerative disorders.

HF0220 successfully completed a Phase II safety and tolerability study  in patients with mild to moderate Alzheimer-s disease (AD).

This 28 day, multinational, randomized, double blind, placebo controlled pilot study was performed in 42 patients. HF0220 was administered at doses ranging from 1 to 220 mg per day versus placebo. Patients were allowed to continue their current AD medication.

The very high rate of completion of the study by patients, the absence of clinically relevant or statistically significant changes in safety measures, and the very low number of patients experiencing any adverse events, indicate that HF0220 can be safely administered to patients with AD who often experience multiple concomitant illnesses and who are more susceptible to the side-effects of their usual medications.